Latest Biologicals News

Cleo Diagnostics’ prototype ovarian cancer screening test met or exceeded every predefined performance target in a 247-person proof-of-concept study, including among 62 Stage I cases. The result moves the program into larger bridging and expanded studies, but it remains retrospective evidence rather than a validated screening test.

Delorean has secured the operational licence needed for its SA1 Salisbury bioenergy project to begin receiving organic waste, with construction about 90% complete. The approval moves the facility into waste acceptance and biological commissioning ahead of its planned biomethane export into Adelaide’s gas network.

Mesoblast has reported a sharp first-quarter commercial improvement, with Ryoncil revenue rising 44% and net operating cash spend falling 85% year on year. The company ended September with US$99 million in cash, although the figures remain preliminary.

RareX has moved Cummins Range through key permitting and heritage milestones, while stronger metallurgical results broaden the project’s critical-minerals potential. But the explorer’s annual loss widened to A$5.07 million, cash burn remained high and its going-concern assessment still depends on future funding and project development.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

Delegat Group delivered record operating earnings and cash flow in FY26, but reported profit fell after a NZ$8.7 million impairment and other fair-value adjustments. The NZX-listed wine company is forecasting higher case sales and operating NPAT of NZ$62 million to NZ$66 million for FY27.

Nufarm is pairing a narrower crop-protection portfolio with heavier investment in seeds and tighter capital controls as it targets A$370 million to A$380 million in FY26 underlying EBITDA. The company has reaffirmed positive free cash flow, leverage of about 2.0 times and a A$50 million cost-saving program due to reach run-rate by the end of FY27.

Murray Cod Australia posted a $5.37 million FY2026 loss after the prior year’s $8.56 million profit, despite higher fish biomass and improved fourth-quarter performance. The company ended the year with $4.14 million in cash after raising capital, while operating cash outflow reached $26.57 million and a Westpac interest-cover covenant was breached and waived.

OD6 Metals has transformed its portfolio with the completed acquisition of Nevada’s Quinn Fluorspar Project, but the strategic expansion comes alongside a larger loss, ongoing funding needs and substantial permitting risk. The company is now targeting drilling and a maiden resource at Quinn while advancing laboratory-scale rare earth processing work at Splinter Rock.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

Neurotech International has dosed the first patient in its pivotal Phase 3 Beyond Harmony study of NTI164, moving the autism therapy into its most consequential clinical test yet. The trial plans to enrol up to 200 children across six Australian sites, but no Phase 3 efficacy data are available at this stage.

OD6 Metals has submitted a Plan of Operations covering up to 139 drill pads and bulk sampling at its Quinn Fluorspar Project in Nevada. The application moves the project towards its first systematic drilling campaign, but approval from the U.S. Forest Service remains outstanding.